Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ995MR)

This product GTTS-WQ995MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ995MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14798MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ9379MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ8582MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ2007MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ6220MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ13775MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ4624MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ7974MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GX-17
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW